KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Current Assets (2017 - 2025)

Novartis Ag's Current Assets history spans 9 years, with the latest figure at $30.5 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 2.55% year-over-year to $30.5 billion; the TTM value through Dec 2025 reached $30.5 billion, up 2.55%, while the annual FY2025 figure was $30.5 billion, 2.55% up from the prior year.
  • Current Assets for Q4 2025 was $30.5 billion at Novartis Ag, up from $29.7 billion in the prior quarter.
  • Across five years, Current Assets topped out at $45.7 billion in Q4 2021 and bottomed at $29.7 billion in Q4 2024.
  • The 5-year median for Current Assets is $30.5 billion (2023), against an average of $34.7 billion.
  • The largest annual shift saw Current Assets soared 54.07% in 2021 before it fell 19.27% in 2022.
  • A 5-year view of Current Assets shows it stood at $45.7 billion in 2021, then fell by 19.27% to $36.9 billion in 2022, then fell by 17.42% to $30.5 billion in 2023, then dropped by 2.55% to $29.7 billion in 2024, then increased by 2.55% to $30.5 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Current Assets are $30.5 billion (Q4 2025), $29.7 billion (Q4 2024), and $30.5 billion (Q4 2023).